Thiethylperazine
Thiethylperazine is a phenothiazine antipsychotic with potent dopamine D2 receptor antagonist activity, used clinically as an antiemetic for the prevention and treatment of nausea and vomiting, including postoperative nausea and chemotherapy-induced emesis, through blockade of dopamine receptors in the chemoreceptor trigger zone. It also blocks muscarinic, histaminergic, and alpha-adrenergic receptors, contributing to its antiemetic efficacy and adverse effect profile. Its use has declined with the availability of more selective antiemetic agents.
Molecular Weight
399.6000 g/mol
LogP
5.40
TPSA
60.30 Ų
Lipinski RO5
Pass
Therapeutic Areas
Mechanism of Action
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
2D Structure
Cite this structure
Embed this structure
SMILES
CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2
InChI
InChI=1S/C22H29N3S2/c1-3-26-18-9-10-22-20(17-18)25(19-7-4-5-8-21(19)27-22)12-6-11-24-15-13-23(2)14-16-24/h4-5,7-10,17H,3,6,11-16H2,1-2H3
Molecular Formula
C22H29N3S2
HBD / HBA
- / 5
Rotatable Bonds
6
Heavy Atoms
27
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
Thiethylperazine is a phenothiazine antipsychotic with potent dopamine D2 receptor antagonist activity, used clinically as an antiemetic for the prevention and treatment of nausea and vomiting, including postoperative nausea and chemotherapy-induced emesis, through blockade of dopamine receptors in the chemoreceptor trigger zone. It also blocks muscarinic, histaminergic, and alpha-adrenergic receptors, contributing to its antiemetic efficacy and adverse effect profile. Its use has declined with the availability of more selective antiemetic agents.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Thiethylperazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1378. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5440. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="thiethylperazine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/thiethylperazine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/thiethylperazine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/thiethylperazine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="thiethylperazine"></drugfyi-drug>